IL2 and neoplasm: The addition of standard local (i.t.)immunotherapy such as i.t. IL-2, or systemic immunotherapy such as an anti-PD-1 inhibitor, further enhanced this immune response by shifting the TME towards a more pro-inflammatory anti-tumor environment, thereby promoting prolonged suppression of tumor growth.